ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Oxygenated Hypothermic Machine Perfusion of Kidneys Donated after Circulatory Death: An International Randomised Controlled Trial

I. Jochmans1, H. S. Hofker2, L. Davies3, S. Knight3, J. Pirenne1, R. J. Ploeg3, -. on behalf of COPE and participating centres4

1Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium, 2University Medical Center Groningen, Groningen, Netherlands, 3University of Oxford, Oxford, United Kingdom, 4Belgium, Netherlands, United Kingdom

Meeting: 2019 American Transplant Congress

Abstract number: 2

Keywords: Donors, non-heart-beating, Graft function, Kidney, Machine preservation

Session Information

Session Name: Plenary Session I

Session Type: Plenary Session

Date: Sunday, June 2, 2019

Session Time: 8:30am-9:45am

 Presentation Time: 8:45am-9:00am

Location: Veterans Auditorium

*Purpose: An international, double-blinded, randomised, paired phase 3 trial designed to determine the effect on 1-year graft function of continuous oxygenated (HMPO) vs non-oxygenated hypothermic machine perfusion (HMP) in controlled DCD kidneys from donors aged 50 years or older.

*Methods: At randomisation, one kidney from each donor was assigned to HMPO, the other to HMP. Kidneys were pumped immediately after retrieval until transplantation. The primary endpoint was estimated glomerular filtration rate (eGFR) at 1 year post-transplant (CKD-EPI) with 90% power at α=0.05 to detect a 8 ml/min/1.73m² difference. A pre-specified sensitivity analysis accounted for cases where no eGFR at 1 year was available due to graft loss (eGFR imputed by 10 mL/min/1.73m²) or patient death with functioning graft (last known eGFR carried forward). Secondary endpoints were delayed graft function, primary nonfunction, graft loss, and patient death. The primary analysis was performed according to intention to treat.

*Results: Belgium, the Netherlands, and part of the UK randomised 197 kidney pairs (median donor age 56 (range: 50-78) years), of which 106 were successfully machine perfused and transplanted (median recipient age 61 (21-79) years). Median total warm ischemia time was 28.5 (8-114) minutes and cold time was 11 (4.6-27.6) hours in HMPO and 10.3 (3.5-27.1) hours in HMP. Kidneys were pumped for 6.9 (1.7-24.3) vs 7.4 (1.3-23.8) hours. For the primary analysis, 83 pairs were eligible for inclusion (23 pairs excluded due to all-cause graft failure of at least 1 kidney). No difference in eGFR at 1 year was observed between HMPO vs HMP (mean(SE): 50.5(2.1) vs 46.7(1.8) mL/min/1.73m², p=0.12). However, sensitivity analysis, accounting for all-cause graft failure, showed a higher eGFR in HMPO (47.6(1.9) vs 42.6(2.0) mL/min/1.73m², p=0.035). Graft loss was significantly lower after HMPO; other secondary outcomes including patient death were similar between the two groups (Table).

*Conclusions: This first randomised controlled trial comparing HMPO with HMP suggests that oxygenation improves 1 year kidney graft function when accounting for the beneficial effect on graft survival.

Outcomes after transplantation according to treatment group
HMPO (n=106) HMP (n=106) p-value
Primary nonfunction 3 (2.8%) 5 (4.7%) 0.48
Delayed graft function 38 (35.8%) 38 (35.8%) 0.99
Graft loss 3 (2.8%) 11 (10.4%) 0.021
Patient death 7 (6.6%) 8 (7.5%) 0.80
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Jochmans I, Hofker HS, Davies L, Knight S, Pirenne J, Ploeg RJ. Oxygenated Hypothermic Machine Perfusion of Kidneys Donated after Circulatory Death: An International Randomised Controlled Trial [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/oxygenated-hypothermic-machine-perfusion-of-kidneys-donated-after-circulatory-death-an-international-randomised-controlled-trial/. Accessed May 12, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences